EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Effects of Palliative Chemotherapy in Unresectable or Metastatic Colorectal Cancer Patients With Poor Performance Status

Lucila Soares da Silva Rocha, Camila Motta Venchiarutti Moniz, Marilia Polo Mingueti E Silva, Guilherme Fialho de Freitas, Virgilio Souza E Silva, Paulo Marcelo Gehm Hoff, Rachel P Riechelmann

Clinical Colorectal Cancer · 2023

DOI: 10.1016/j.clcc.2023.05.001 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Colorectal Cancer, 2023. Verfasst von Lucila Soares da Silva Rocha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Postgraduate Education in Clinical Oncology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Oncology Clinical R…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Colorectal cancer is the second most common cancer in both genders and often presents as a metastatic, unresectable, or recurrent disease in early follow-up. It is uncertain the benefit of oxaliplatin-based palliative chemotherapy (CT) in the first line of treatment in patients with compromised performance status (PS), Eastern Cooperative Oncology Group (ECOG) 3 and 4. These patients are systematically excluded from clinical trials but may be treated in clinical practice. METHODS: We conducted a prospective observational cohort whose primary outcome was improving at least 2 points in the worst symptom in the Edmonton Symptom Assessment System Scale (ESAS-r), without grade 3 to 4 toxicity, comparing baseline and fourth week of treatment. Secondary endpoints included quality of life using the European Quality of Life-5 dimensions questionnaire, toxicity, response rate, clinical improvement of ECOG PS, and overall survival (OS). RESULTS: We included 28 patients, and 12 (42.8%) achieved the primary endpoint. Median overall survival was 86 days, 46% of patients did not respond to the fourth-week reevaluation due to clinical deterioration, and 17.8% presented toxicity grade ≥3, with 5 patients dying from toxicity. In addition, ECOG PS 4 or cholestasis had poorer overall survival. Finally, 25% and 53.6% of patients received these treatments in the last 14 and 30 days of life, respectively. CONCLUSION: In the present study, palliative multiagent chemotherapy in poor performance status patients with non-molecularly selected colorectal cancer tended to impact tumor symptoms control; however, there is no benefit in OS and a considerable risk of toxicity and treatment-related death.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsRectal NeoplasmsColorectal NeoplasmsHumansMaleFemaleQuality of LifeOxaliplatinAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

FrailtyNeoplasm MetastasisOxaliplatin

Substanzen

Oxaliplatin

Autor:innen und Institutionen

  • Department of Postgraduate Education in Clinical Oncology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Oncology Clinical Research Department, Instituto D'Or de Pesquisa e Ensino, São Paulo-SP,…
  • Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo - FMUSP, São Paulo, Brazil; Department of Postgraduate Education in Clinical Oncology, Facu…
  • Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo - FMUSP, São Paulo, Brazil.
  • Department of Clinical Oncology, AC Camargo Cancer Center, São Paulo, Brazil.
  • Department of Postgraduate Education in Clinical Oncology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Department of Clinical Oncology, AC Camargo Cancer Center, São Paulo, Brazil.

Zitieren

APA

da Silva Rocha, L. S., Moniz, C. M. V., Mingueti E Silva, M. P., de Freitas, G. F., Souza E Silva, V., Hoff, P. M. G., & Riechelmann, R. P. (2023). Effects of Palliative Chemotherapy in Unresectable or Metastatic Colorectal Cancer Patients With Poor Performance Status. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2023.05.001

Vancouver

da Silva Rocha LS, Moniz CMV, Mingueti E Silva MP, de Freitas GF, Souza E Silva V, Hoff PMG, et al. Effects of Palliative Chemotherapy in Unresectable or Metastatic Colorectal Cancer Patients With Poor Performance Status. Clinical Colorectal Cancer. 2023. doi:10.1016/j.clcc.2023.05.001

BibTeX
@article{daSilvaRocha2023,
  author = {da Silva Rocha, Lucila Soares and Moniz, Camila Motta Venchiarutti and Mingueti E Silva, Marilia Polo and de Freitas, Guilherme Fialho and Souza E Silva, Virgilio and Hoff, Paulo Marcelo Gehm and Riechelmann, Rachel P},
  title = {Effects of Palliative Chemotherapy in Unresectable or Metastatic Colorectal Cancer Patients With Poor Performance Status},
  journal = {Clinical Colorectal Cancer},
  year = {2023},
  doi = {10.1016/j.clcc.2023.05.001}
}
Kostenlos starten →